[EN] OXYTOCIN RECEPTOR AGONISTS FOR THE TREATMENT OF CNS DISEASES<br/>[FR] AGONISTES DU RÉCEPTEUR D'OXYTOCINE POUR LE TRAITEMENT DE MALADIES DU SYSTÈME NERVEUX CENTRAL
申请人:HOFFMANN LA ROCHE
公开号:WO2014111356A1
公开(公告)日:2014-07-24
The invention relates to the use of a compound of formula I wherein A1 is phenyl or a five or six membered hereroaryl group, containing 1, 2 or 3 heteroatoms, selected from N or S; R1 is hydrogen, lower alkyl, halogen, lower alkyl substituted by halogen or cycloalkyl; A2 is phenyl; R2 is halogen, lower alkyl, lower alkyl substituted by halogen, lower alkoxy substituted by halogen, cyano, S-lower alkyl substituted by halogen, S(O)2-lower alkyl substituted by halogen; n is 1 or 2; or a to pharmaceutically acceptable acid addition salt, to a racemic mixture or to its corresponding enantiomer and/or optical isomers thereof for the treatment of autism, stress, including post traumatic stress disorder, anxiety, including anxiety disorders and depression, schizophrenia, psychiatric disorders and memory loss, alcohol withdrawel, drug addiction and for the treatment of Prader-Willi Syndrom.
该发明涉及使用式I的化合物,其中A1是苯基或含有1、2或3个杂原子(N或S)的五元或六元杂环烷基;R1是氢、低碳链基、卤素、被卤素取代的低碳链基或环烷基;A2是苯基;R2是卤素、低碳链基、被卤素取代的低碳链基、被卤素取代的低碳氧基、氰基、被卤素取代的S-低碳链基、被卤素取代的S(O)2-低碳链基;n为1或2;或其药学上可接受的酸盐,用于治疗自闭症、压力(包括创伤后应激障碍)、焦虑(包括焦虑症和抑郁症)、精神分裂症、精神障碍和记忆丧失、酒精戒断、药物成瘾以及普拉德-威利综合征。